Extending landscape of volatile metabolites as novel diagnostic biomarkers of inflammatory bowel disease – a review

References

• Vermeire S, Peeters M, Rutgeerts P. Diagnostic approach to IBD. Hepatogastroenterology. 2000;47:44–48.
   PubMed Web of Science ®Google Scholar
• Vrabie R, Kane S. Noninvasive markers of disease activity in inflammatory bowel disease. Gasttroenterol Hepatol. 2014;10:1109–1111.
   Google Scholar
• Tibble J, Bjarnason I. Non-invasive investigation of inflammatory bowel disease. World J Gastroenterol. 2001;7:460–465.
   PubMed Web of Science ®Google Scholar
• Vermeire S, Van Assche G, Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis. 2004;10:661–665.
   PubMed Web of Science ®Google Scholar
• Stacy B, Menees C, Powell J, et al. A meta-analysis of the utility of c-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. Am J Gastroenterol. 2015;110:444–454.
   PubMed Web of Science ®Google Scholar
• Boirivant M, Tariciotti D, Fais S, et al. The clinical significance of serum C reactive protein levels in Crohn's disease. Results of a prospective longitudinal study. J Clin Gastroenterol. 1988;10:401–405.
   PubMed Web of Science ®Google Scholar
• Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut. 2006;55:426–431.
   PubMed Web of Science ®Google Scholar
• Waugh N, Royle P, Cummins E, et al. Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation. Health Tech Assessment. 2013;17:201–211.
   Google Scholar
• Von Roon AC, Purkayastha S, Reese GE, et al. Diagnostic precision of faecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol. 2007;102:803–813.
   PubMed Web of Science ®Google Scholar
• Roseth AG, Aadland E, Jahnsen J, et al. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion. 1997;58:176–180.
   PubMed Web of Science ®Google Scholar
• van Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ. 2010;341:c3369.
   PubMed Web of Science ®Google Scholar
• Parsi MA, Shen B, Achkar J-P, et al. Faecal lactoferrin for diagnosis of symptomatic patients with ileal pouch-anal anastomosis. Gastroenterology. 2004;126:1280–1286.
   PubMed Web of Science ®Google Scholar
• Summerton CB, Longlands MG, Wiener K, et al. Faecal calprotectin: a marker of inflammation throughout the intestinal tract. Eur J Gastroenterol Hepatol. 2002;14:841–845.
   PubMed Web of Science ®Google Scholar
• Cicolella A. Volatile Organic Compounds: definition, classification and properties. Rev Mal Respir. 2008;25:155–163.
   PubMed Web of Science ®Google Scholar
• Geypens B, Claus D, Evebepoel P, et al. Influence of dietary protein supplements on the formation of bacterial metabolites in the colon. Gut. 1997;41:70–76.
   PubMed Web of Science ®Google Scholar
• Spanel P, Smith D. Volatile compounds in health and disease. Curr Opin Clin Nutr. Metab Care 2011;14:455–460.
   PubMed Web of Science ®Google Scholar
• Di Francesco F, Fuoco R, Trivella MG, et al. Breath analysis: trends in techniques and clinical applications. Microchem J. 2005;79:405–410.
   Web of Science ®Google Scholar
• Dixon E, Clubb C, Pittman S, et al. Solid-phase microextraction and the human faecal VOC metabolome. PloS One. 2011;6:e18471.
   Google Scholar
• Probert CS, Ahmed I, Khalid T, et al. Volatile organic compounds as diagnostic biomarkers in gastrointestinal and liver diseases. J Gastrointestin Liver Dis. 2009 Sep;18:337–343.
   PubMed Web of Science ®Google Scholar
• Pauling L, Teranishi R, Cary P. Quantitative Analysis of Urine Vapor and Breath by Gas-Liquid Partition Chromatography. Proc Natl Acad Sci USA. 1971;68:2374–2376.
   PubMed Web of Science ®Google Scholar
• Phillips M, Krishnan S, Zain M, et al. Variation in volatile organic compounds in the breath of normal human. J Chromatogr B Biomed Sci Appl. 1999;11:75–88.
   Web of Science ®Google Scholar
• Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care. 1996;19:257–267.
   PubMed Web of Science ®Google Scholar
• Dragonieri S, Schot R, Mertens BJA, et al. An electronic nose in the discrimination of patients with asthma and controls. J Allergy Clin Immunol. 2007;120:856–862.
   PubMed Web of Science ®Google Scholar
• Ondrula D, Andrianopoulos G, Schwartz D, et al. Quantitative determination of pentane in exhaled air correlates with colonic inflammation in the rat colitis model. Dis Colon Rectum. 1993;36:457–462.
   PubMed Web of Science ®Google Scholar
• Kokoszka J, Swedler WI, Skosey J, et al. Determination of inflammatory bowel disease activity by breath pentane analysis. Dis Colon Rectum. 1993;36:597–601.
   PubMed Web of Science ®Google Scholar
• Pelli MA, Capodicasa E, De Medio GE, et al. Breath alkanes determination in ulcerative colitis and Crohn's disease. Dis Colon Rectum. 1999;42:71–76.
   PubMed Web of Science ®Google Scholar
• Sedghi S, Klamut M, Eiznhamer D, et al. Elevated breath ethane levels in active ulcerative colitis: evidence for excessive lipid peroxidation. Am J Gastroenterol. 1994;89:2217.
   PubMed Web of Science ®Google Scholar
• Kurada S, Alkhouri N, Fiocchi C, et al. Review article: breath analysis in inflammatory bowel diseases. Aliment Pharmocol Ther. 2014;41:329–341.
   PubMed Web of Science ®Google Scholar
• Suarez F, Furne J, Springfield J, et al. Insights into human colonic physiology obtained from the study of flatus composition. Am J Physiol. 1997;272:G1028–G1033.
   PubMedGoogle Scholar
• Seksik P, Rigottier-Gois L, Gramet G, et al. Alterations of the dominant faecal bacterial groups in patients with Crohn's disease of the colon. Gut. 2003;52:237–242.
   PubMed Web of Science ®Google Scholar
• Garner CE, Smith S, Elviss NC, et al. Identification of Campylobacter infection in chickens from volatile faecal emissions. Biomarkers. 2008;13:413–421.
   PubMed Web of Science ®Google Scholar
• De Lacy Costello B, Ewer AK, Garner CE, et al. An analysis of volatiles in the headspace of the faeces of neonates. J Breath Res. 2008;2:23–28
   Google Scholar
• Garner CE, Ewer AK, Elasouad K, et al. Analysis of faecal volatile organic compounds in preterm infants who develop necrotising enterocolitis: a pilot study. J Pediatric Gastroenterol Nutr. 2009;49:559–565.
   PubMed Web of Science ®Google Scholar
• Garner CE, Smith S, de Lacy Costello B, et al. Volatile organic compounds from faeces and their potential for diagnosis of gastrointestinal disease. Faseb J. 2007;21:1675–1688.
   PubMed Web of Science ®Google Scholar
• Ahmed I, Greenwood R, Costello BDL, et al. An investigation of faecal volatile organic metabolites in irritable bowel syndrome. PLoS One. 2013;8:e58204.
   PubMed Web of Science ®Google Scholar
• De Preter V, Machiels K, Joossens M, et al. Faecal metabolite profiling identifies medium-chain fatty acids as discriminating compounds in IBD. Gut. 2015;64:447–458.
   PubMed Web of Science ®Google Scholar
• Ahmed I, Probert CS, Smith S, et al. Diagnostic potential of volatile organic compounds in inflammatory bowel disease. Gastroenterology. 2010;138: 763–76S-764.
   Google Scholar
• Fritz KS, Petersen DR. An overview of the chemistry and biology of reactive aldehydes. Free Radic Biol Med. 2013;59:85–91.
   PubMed Web of Science ®Google Scholar
• Kajander K, Myllyluoma E, Kyronpalo S, et al. Elevated pro-inflammatory and lipotoxicmucosal lipids chracterise irritable bowel syndrome. World J Gastroenterol 2009;14:6068–6074.
   Web of Science ®Google Scholar
• Manichanh C, Rigottier-Gois L, Bonnaud E, et al. Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. Gut. 2006;55:205–211.
   PubMed Web of Science ®Google Scholar
• Frank DN, St Amand AL, Feldman RA, et al. Molecular-phylogenetic characterisation of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci USA. 2007;104:13780–13785.
   PubMed Web of Science ®Google Scholar
• Walker AW, Sanderson JD, Churcher C, et al. High-throughput clone library analysis of the mucosa-associated microbiota reveals dysbiosis and differences between inflamed and non-inflamed regions of the intestine in inflammatory bowel disease. BMC Microbiol. 2011;11:7.
   PubMed Web of Science ®Google Scholar
• Machiels K, Joossens M, Sabino J, et al. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut. 2014;63:1275–1283.
   PubMed Web of Science ®Google Scholar
• Sokol H, Pigneur B, Watterlot L, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci USA. 2008;105:16731–16736.
   PubMed Web of Science ®Google Scholar
• Tana C, Umesaki Y, Imaoka A, et al. Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol Motil. 2010 May;22:512–519.
   PubMed Web of Science ®Google Scholar
• Winston J, Shenoy M, Medley D, et al. The vanilloid receptor initiates and maintains colonic hypersensitivity induced by neonatal colon irritation in rats. Gastroenterology. 2007;132:615–627.
   PubMed Web of Science ®Google Scholar
• Read S, Ahmed I, Probert C. Fecal volatile organic compounds: a novel, cheaper method of diagnosing inflammatory bowel disease. Expert Rev Clin Immunol. 2014;10:1129–1131.
   PubMed Web of Science ®Google Scholar
• Zlatkis A, Liebich HM. Profile of volatile metabolites in human urine. Clin Chem. 1971;17:592–594.
   PubMed Web of Science ®Google Scholar
• Arasaradnam RP, Ouaret N, Thomas MG, et al. A novel tool for noninvasive diagnosis and tracking of patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:999–1003.
   PubMed Web of Science ®Google Scholar
• De Preter V. Metabolomics in the clinical diagnosis of inflammatory bowel disease. Dig Dis. 2015;14:2–10.
   Web of Science ®Google Scholar
• Zhang Y, Lin L, Xu Y, et al. 1H NMR-based spectroscopy detects metabolic alterations in serum of patients with early-stage ulcerative colitis. Biochem Biophys Res Commun. 2013;433:547–551.
   PubMed Web of Science ®Google Scholar
• Hisamatsu T, Okamoto S, Hashimoto M, et al. Novel, objective, multivariate biomarkers composed of plasma amino acid profiles for the diagnosis and assessment of inflammatory bowel disease. PLoS One. 2012;7:e31131.
   PubMed Web of Science ®Google Scholar